WHITEHOUSE STATION, N.J. (AP) — Merck & Co., one of the world’s top developers and sellers of vaccines, has entered a partnership with a small drug developer to research and manufacture a potential Ebola vaccine now in initial patient testing.
The exclusive deal involves a vaccine candidate called rVSV-EBOV that’s under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of Ames, Iowa.READ MORE: 2022 Wawa Welcome America Festival Guide: Road Closures, Public Transportation Information
The vaccine was originally created in labs of the Public Health Agency of Canada, which in 2010 signed a deal giving BioProtection Systems an exclusive license for the vaccine and the technology involved in producing it.READ MORE: Fourth Of July Weekend Weather: Severe Thunderstorm Watch Issued For Most Of Philadelphia Region
Under the new deal, Merck, based in Whitehouse Station, New Jersey, gets exclusive rights to the vaccine and any follow-up products.
(© Copyright 2014 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed.)
You may also be interested in these stories:
[display-posts category=”news” wrapper=”ul” posts_per_page=”5″]